Comparison
BPC-157 vs Vitamin D3 + K2
Side-by-side of BPC-157 and Vitamin D3 + K2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Vitamin D3 + K2
Vitamin D3 K2 supplement profile: cholecalciferol at 1000-4000 IU/day corrects deficiency, MK-7 directs calcium to bone, away from arteries.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Vitamin D3 + K2
- •Reduces non-vertebral fractures 10-20% in older adults at 800 IU/day or above when combined with calcium
- •VITAL trial showed neutral results on primary CV and cancer endpoints at 2000 IU/day over 5 years
- •Vitamin D supplementation reduces respiratory infection incidence ~10-20% in deficient populations
- •K2 MK-7 has 72-hour plasma half-life vs 1-2 hours for MK-4; once-daily dosing is sufficient
- •Synergy hypothesis is largely preclinical; dedicated combination RCTs are limited
- •Daily dosing outperforms bolus dosing for immune and infection outcomes
Side-by-side
| Attribute | BPC-157 | Vitamin D3 + K2 |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | cholecalciferol + menaquinone, D3/K2, vitamin D3 with MK-7 |
| Half-life (hr) ↗ | 4 | 360 |
| Typical dose (mg) ↗ | 0.25 | 0.05 |
| Dosing frequency | daily (anecdotal protocols) | daily with a fat-containing meal |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 24 |
| Peak (hr) | - | 168 |
| Molecular weight | - | 384.64 |
| Molecular formula | C62H98N16O22 | C27H44O (D3); C46H64O2 (MK-7) |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | D3 converts to calcidiol then calcitriol, activating the vitamin D receptor (VDR) to increase intestinal calcium absorption and modulate immune and bone gene transcription. K2 carboxylates osteocalcin and matrix Gla protein, directing calcium toward bone and inhibiting vascular calcification. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Dietary supplement (global) |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data | Recommended at standard doses for fetal bone development; consult clinician at higher doses |
| CAS | 137525-51-0 | 67-97-0 |
| PubChem CID | 9941957 | 5280795 |
| Wikidata | Q4835418 | Q139347 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Vitamin D3 + K2
Common side effects
- GI upset at high doses
- headache (rare)
- hypercalcemia (only at sustained very high D3 doses)
Contraindications
- hypercalcemia
- sarcoidosis
- active hyperparathyroidism
- warfarin therapy (K2 component requires stable intake)
Interactions
- warfarin: K2 component can affect anticoagulation; maintain stable intake and inform anticoagulation clinic(moderate)
- thiazide diuretics: additive calcium retention; hypercalcemia risk with high-dose D3(moderate)
- digoxin and calcium channel blockers: additive effects from D3-induced hypercalcemia(moderate)
- glucocorticoids: reduced vitamin D efficacy and bone effects(moderate)
- cholestyramine and orlistat: bind fat-soluble vitamins; separate dosing by 2 to 4 hours(moderate)
Which Should You Take?
Vitamin D3 + K2 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is bone density, pick Vitamin D3 + K2.
- → If your priority is healthspan extension, pick Vitamin D3 + K2.
Edge case: If you want to avoid research-only / gray-market sourcing, Vitamin D3 + K2 is the more accessible choice.
Default choice: Vitamin D3 + K2. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Vitamin D3 + K2?
BPC-157 and Vitamin D3 + K2 differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Vitamin D3 + K2?
BPC-157 half-life is 4 hours; Vitamin D3 + K2 half-life is 360 hours.
Can you stack BPC-157 with Vitamin D3 + K2?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper